A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

NCT01519492 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Skin and Subcutaneous Tissue Bacterial Infections
Wound Infection
Cutaneous Abscess
Burn Infection
Cellulitis

Interventions

DRUG: AFN-12520000

Sponsor

Affinium Pharmaceuticals, Ltd